Insider Selling: Aduro BioTech Inc (ADRO) Insider Sells 6,081 Shares of Stock

Aduro BioTech Inc (NASDAQ:ADRO) insider Elsas Andrea Van sold 6,081 shares of the business’s stock in a transaction on Tuesday, March 19th. The shares were sold at an average price of $3.96, for a total transaction of $24,080.76. Following the transaction, the insider now owns 239,557 shares of the company’s stock, valued at $948,645.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Elsas Andrea Van also recently made the following trade(s):

  • On Tuesday, February 26th, Elsas Andrea Van sold 6,844 shares of Aduro BioTech stock. The shares were sold at an average price of $4.25, for a total transaction of $29,087.00.
  • On Friday, December 28th, Elsas Andrea Van sold 1,907 shares of Aduro BioTech stock. The shares were sold at an average price of $2.57, for a total transaction of $4,900.99.
  • On Friday, December 28th, Elsas Andrea Van sold 1,907 shares of Aduro BioTech stock. The shares were sold at an average price of $2.57, for a total transaction of $4,900.99.

ADRO traded down $0.04 on Thursday, reaching $3.87. The stock had a trading volume of 282,500 shares, compared to its average volume of 789,124. Aduro BioTech Inc has a 12-month low of $2.34 and a 12-month high of $9.85. The stock has a market capitalization of $310.87 million, a price-to-earnings ratio of -3.34 and a beta of 2.08.

Aduro BioTech (NASDAQ:ADRO) last released its quarterly earnings data on Wednesday, February 27th. The biotechnology company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.10). Aduro BioTech had a negative net margin of 632.05% and a negative return on equity of 54.84%. On average, analysts predict that Aduro BioTech Inc will post -0.78 earnings per share for the current year.

ADRO has been the subject of a number of recent analyst reports. Zacks Investment Research raised shares of Aduro BioTech from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a report on Wednesday, December 5th. HC Wainwright reaffirmed a “buy” rating and issued a $8.30 price objective on shares of Aduro BioTech in a report on Wednesday, December 19th. BidaskClub raised shares of Aduro BioTech from a “sell” rating to a “hold” rating in a report on Thursday, February 14th. Finally, Oppenheimer reaffirmed a “buy” rating on shares of Aduro BioTech in a report on Tuesday. One analyst has rated the stock with a sell rating, three have issued a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $7.41.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. MetLife Investment Advisors LLC increased its stake in shares of Aduro BioTech by 55.2% during the third quarter. MetLife Investment Advisors LLC now owns 49,337 shares of the biotechnology company’s stock worth $363,000 after purchasing an additional 17,538 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Aduro BioTech by 138.5% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,402 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 7,202 shares in the last quarter. AXA increased its stake in shares of Aduro BioTech by 85.9% during the third quarter. AXA now owns 42,756 shares of the biotechnology company’s stock worth $314,000 after purchasing an additional 19,756 shares in the last quarter. Baillie Gifford & Co. increased its stake in shares of Aduro BioTech by 9.5% during the third quarter. Baillie Gifford & Co. now owns 3,076,825 shares of the biotechnology company’s stock worth $22,615,000 after purchasing an additional 266,317 shares in the last quarter. Finally, Aquilo Capital Management LLC increased its stake in shares of Aduro BioTech by 4.8% during the third quarter. Aquilo Capital Management LLC now owns 2,105,282 shares of the biotechnology company’s stock worth $15,474,000 after purchasing an additional 97,383 shares in the last quarter. 44.73% of the stock is owned by institutional investors.

WARNING: This news story was originally published by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this news story on another publication, it was illegally copied and republished in violation of U.S. & international copyright and trademark law. The original version of this news story can be read at https://sportsperspectives.com/2019/03/21/insider-selling-aduro-biotech-inc-adro-insider-sells-6081-shares-of-stock.html.

Aduro BioTech Company Profile

Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.

Featured Article: What is the price-to-earnings growth (PEG) ratio?

Insider Buying and Selling by Quarter for Aduro BioTech (NASDAQ:ADRO)

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.